QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients

被引:14
|
作者
Nussinovitch, Udi [1 ]
Kaminer, Keren [2 ]
Nussinovitch, Moshe [2 ,3 ]
Volovitz, Benjamin [2 ,3 ]
Lidar, Merav [2 ,4 ,6 ]
Nussinovitch, Naomi [2 ,5 ,7 ]
Livneh, Avi [2 ,4 ,6 ]
机构
[1] IDF Med Corps, Israel Naval Med Inst, IL-31080 Haifa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Schneider Childrens Med Ctr Israel, Dept Pediat C, Petah Tiqwa, Israel
[4] Chaim Sheba Med Ctr, Heller Inst Med Res, IL-52621 Tel Hashomer, Israel
[5] Chaim Sheba Med Ctr, Hypertens Unit, IL-52621 Tel Hashomer, Israel
[6] Chaim Sheba Med Ctr, Dept Med F, IL-52621 Tel Hashomer, Israel
[7] Chaim Sheba Med Ctr, Dept Internal Med D, IL-52621 Tel Hashomer, Israel
关键词
Arrhythmia; Familial Mediterranean fever; QT dispersion (QTd); QT variability index (QTVI); DISPERSION; ATHEROSCLEROSIS; REPOLARIZATION; DIAGNOSIS; DISEASE;
D O I
10.1007/s10067-011-1926-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The association between familial Mediterranean fever (FMF), early atherosclerosis, and electrocardiographic markers for arrhythmias remains controversial. There are conflicting results as to the occurrence of high QT dispersion in FMF. The aim of the present study was to further investigate repolarization dynamics and other repolarization-associated pro-arrhythmogenic markers in FMF patients. To explore repolarization in FMF, patients who responded well to colchicine and patients who had not responded to colchicine, yet were amyloidosis-free, were included. We aimed to evaluate whether increased inflammatory burden, a characteristic of non-responsive patients, was specifically associated with abnormal repolarization. Included in the study were 53 FMF patients (27 colchicine non-responders) and 53 age- and sex-matched control subjects. Electrocardiograms were performed under strict standards. QT variability parameters were computed with custom-made computer software. No significant difference in any of the QT dynamic parameters was found in either FMF group compared with the healthy controls. Mean values of QT variability index, regardless of colchicine response, were similar to previously published results for healthy persons. In conclusion, patients with FMF who are continuously treated with colchicine and have not developed amyloidosis, regardless of their clinical response, have normal QT variability parameters, indicating normal repolarization dynamics and suggesting no increased risk of repolarization-associated cardiac arrhythmias.
引用
收藏
页码:795 / 799
页数:5
相关论文
共 50 条
  • [21] The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey
    Sahin, Nihal
    Ozdemir Cicek, Sumeyra
    Pac Kisaarslan, Aysenur
    Poyrazoglu, Muammer Hakan
    Gunduz, Zubeyde
    Dusunsel, Ruhan
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 177 - 185
  • [22] The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: A pilot study
    Tunca, M
    Tankurt, E
    Akpinar, HA
    Akar, S
    Hizli, N
    Gonen, O
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1005 - 1008
  • [23] Severity scores, damage indices, and the concept of the colchicine-resistant patient in familial Mediterranean fever
    Er, Ozan
    Akay, Helin
    Ozgozen, Mehmet Emre
    Gulhan, Didem
    Ugurlu, Serdal
    MODERN RHEUMATOLOGY, 2024, : 7 - 16
  • [24] Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
    Ahmet Gül
    Huri Ozdogan
    Burak Erer
    Serdal Ugurlu
    Ozgur Kasapcopur
    Nicole Davis
    Serhan Sevgi
    Arthritis Research & Therapy, 17
  • [25] IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
    Koehler, Birgit Maria
    Lorenz, Hanns-Martin
    Blank, Norbert
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2018, 5 (04) : 230 - 234
  • [26] Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram
    Toshida, Masamitsu
    Konishi, Yuki
    Ikenouchi, Atsuko
    Okamoto, Naomichi
    Yoshimura, Reiji
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)
  • [27] An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study
    Shehadeh, Katy
    Levinsky, Yoel
    Kagan, Shelly
    Zuabi, Tarek
    Tal, Rotem
    Aviran, Neta Hana
    Aviel, Yonatan Butbul
    Tirosh, Irit
    Spielman, Shiri
    Miller-Barmak, Adi
    Oz, Rotem Semo
    Harel, Liora
    Chodick, Gabriel
    Amarilyo, Gil
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 132
  • [28] Colchicine-responsive chronic recurrent multifocal osteomyelitis with MEFV mutations: a variant of familial Mediterranean fever?
    Shimizu, Masaki
    Tone, Yumi
    Toga, Akiko
    Yokoyama, Tadafumi
    Wada, Taizo
    Toma, Tomoko
    Yachie, Akihiro
    RHEUMATOLOGY, 2010, 49 (11) : 2221 - 2223
  • [29] Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study
    Tomokawa, Takuya
    Koga, Tomohiro
    Endo, Yushiro
    Michitsuji, Toru
    Kawakami, Atsushi
    MODERN RHEUMATOLOGY, 2022, 32 (04) : 797 - 802
  • [30] The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients
    Calguneri, M
    Apras, S
    Ozbalkan, Z
    Ozturk, MA
    Ertenli, I
    Kiraz, S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (04) : S41 - S44